Vor Biopharma (NYSE:VOR) Given “Outperform” Rating at Wedbush

Wedbush restated their outperform rating on shares of Vor Biopharma (NYSE:VOR) in a research report sent to investors on Friday,RTT News reports. They currently have a $11.00 price objective on the stock.

Other analysts have also recently issued research reports about the stock. JMP Securities reiterated a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a research note on Friday, September 6th. HC Wainwright reiterated a “buy” rating and issued a $17.50 price objective on shares of Vor Biopharma in a research note on Friday. Robert W. Baird dropped their price objective on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating for the company in a research note on Friday. Finally, Barclays dropped their price objective on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating for the company in a research note on Wednesday, August 14th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Vor Biopharma currently has a consensus rating of “Buy” and an average target price of $11.36.

Vor Biopharma Stock Performance

Shares of VOR stock opened at $1.01 on Friday. The company has a market capitalization of $69.08 million, a price-to-earnings ratio of -0.61 and a beta of -0.40. The company has a 50-day simple moving average of $0.80 and a 200 day simple moving average of $1.06. Vor Biopharma has a 52 week low of $0.63 and a 52 week high of $3.14.

Vor Biopharma (NYSE:VOR) last announced its earnings results on Thursday, November 7th. The company reported ($0.40) EPS for the quarter, hitting the consensus estimate of ($0.40). Sell-side analysts forecast that Vor Biopharma will post -1.51 EPS for the current year.

Hedge Funds Weigh In On Vor Biopharma

Several hedge funds and other institutional investors have recently made changes to their positions in VOR. Renaissance Technologies LLC increased its position in Vor Biopharma by 48.0% during the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock worth $495,000 after purchasing an additional 160,642 shares in the last quarter. Rosalind Advisors Inc. acquired a new position in Vor Biopharma during the 3rd quarter worth approximately $54,000. Vanguard Group Inc. increased its position in Vor Biopharma by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock worth $4,297,000 after purchasing an additional 69,436 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Vor Biopharma during the 2nd quarter worth approximately $63,000. Finally, Acadian Asset Management LLC acquired a new position in Vor Biopharma during the 1st quarter worth approximately $126,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.